Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New ECCO studies highlight promising potential of cancer immunotherapy

03.11.2005


New research findings showcased at the 13th European Cancer Conference (ECCO) have highlighted the important therapeutic potential of immunotherapy in the treatment of a number of different cancers e.g. for treatment of renal and skin cancers.



Renal cancer is the 6th leading cause of cancer death with a survival rate of 11% for stage-IV disease. More than a million skin cancer cases occur each year globally, with a 5-year survival rate of 7 to 9% and a 10-year survival rate of 3 to 6% for stage IV melanoma. These cancers are associated with significant mortality for which survival statistics have remained essentially unchanged for several decades. Past studies have indicated vaccination as a route to boosting anti-tumour T-cell reponses to help kill malignant cells. US investigator Dr Arkadiusz Dudek, from the University of Minnesota, and his team have developed a new method of vaccine-induced augmentation of tumour specific cytotoxic T-lymphocyte responses with the use of latex or silica beads.

The new large multivalent immunogen (LMI) was trialed in 61 patients with renal cancer or malignant melanoma with positive results.


In renal cancer patients, the LMI vaccine was found to prolong time to disease progression to 12.2 months. A significant increase when compared to the standard therapy of renal cancer (high dose interleukin-2) which produced a median progression-free survival of 3.1 months1. Using indicators of median overall survival, patients treated with high dose interleukin-2 survived 17.5 months1 and those treated with the LMI vaccine survived longer than 17.04 months and at current follow up, more than 19 months.

“Our study findings offer hope for patients with metastastic renal cell carcinoma, as this therapy stabilises and controls disease for an average of one year. For patients with metastastic malignant melanoma a large multivalent immunogen vaccine strategy needs to be optimised in order to obtain reproducible results. We hope that by utilising an allogeneic (using human donor cells/tissue) strategy we will observe more frequent and longer lasting responses. This vaccine strategy has no toxicities and treatment is convenient for patients as the vaccine is administered only once a month. In contrast, standard therapeutic strategy using high dose interleukin-2 is very toxic and limited only to selected patients with good performance status, and no cardiac or pulmonary co-morbidities,” noted Dr Dudek.

Another immunotherapeutic approach which seeks to boost the responses of effector CD8+ T-cells are DEX vaccines; Dendritic cell derived-EXosomes. In results presented at ECCO, the DEX vaccine, in combination with the alkylating agent cyclophosphamide (CTX), was found to produce antitumour effects superior to that obtained with either the peptide Gp100 plus CTX, or the best DEX vaccination approach currently available in a mouse model of melanoma.

In this new immunotherapeutic approach, CTX acts synergistically with DEX to abolish the function of Treg cells – cells induced by the tumour which suppress the CD8+ responses evoked by DEX. By abrogating the suppressive effect of Treg, CTX maximises the curative effects of DEX vaccination. The success of this combination approach suggests that future therapeutic vaccines aimed at boosting tumour-primed effector T-cells may benefit from procedures that minimise the pro-tumour effects of Treg cells.

About Renal Cancer

Renal cancer is defined as malignancy of the kidney, the organ that is primarily responsible for the removal of metabolic waste products from the body. In 2004, there were just under 40,000 incidents of renal cancer and 22,000 deaths across the EU.

About Immunotherapy

Immunotherapy is the treatment to stimulate or restore the ability of the immune (defense) system to fight infection and disease.

Kirsten Mason | alfa
Further information:
http://www.fecs.be/emc.asp?pageId=10&Type=P

More articles from Studies and Analyses:

nachricht WAKE-UP provides new treatment option for stroke patients | International study led by UKE
17.05.2018 | Universitätsklinikum Hamburg-Eppendorf

nachricht First form of therapy for childhood dementia CLN2 developed
25.04.2018 | Universitätsklinikum Hamburg-Eppendorf

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Powerful IT security for the car of the future – research alliance develops new approaches

The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.

Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...

Im Focus: Molecular switch will facilitate the development of pioneering electro-optical devices

A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.

The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

In focus: Climate adapted plants

25.05.2018 | Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

 
Latest News

In focus: Climate adapted plants

25.05.2018 | Event News

Flow probes from the 3D printer

25.05.2018 | Machine Engineering

Less is more? Gene switch for healthy aging found

25.05.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>